Hormone Replacement Therapy in Menopause
Vasomotor and vaginal symptoms are the hallmark symptoms of menopause. The reported prevalence of vasomotor symptoms is 50–82% in women who experience natural menopause. The occurrence of symptoms increases during perimenopause and usually peaks at the actual onset of menopause.
KeywordsMenopausal hormone therapy Postmenopausal Vasomotor symptoms Vulvovaginal symptoms Estrogen plus progestin therapy Estrogen therapy
- 1.ACOG Practice Bulletin 141, January 2014 (Reaffirmed 2016): Management of menopausal symptoms.Google Scholar
- 2.ACOG Practice Bulletin 126, March 2012: Management of gynecological issues in women with breast cancer.Google Scholar
- 3.Position Statement: The 2017 Hormone Therapy Position Statement of the North American Menopause Society.Google Scholar
- 4.ACOG Committee Opinion, August 2012: Compounded bioidentical menopausal hormone therapy.Google Scholar
- 5.Global Consensus on Menopausal Hormone Therapy, 2013: International menopause society and the European menopause and andropause society.Google Scholar
- 6.Executive Summary: Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement 2010.Google Scholar
- 8.ACOG Committee Opinion 2013 (Reaffirmed 2015): postmenopausal estrogen therapy: route of administration and risk of VTE.Google Scholar
- 9.KEEPS Report, NAMS 2012 Meeting. www.menopause.org.
- 10.Manson, Kaunitz NEJM 2016 Menopause management-getting clinical care back on track.Google Scholar
- 11.Hormone Therapy and Alternative Therapies for Menopause, ACOG: Clinical Updates in Women’s Health Care. Volume XIV, Number 4., October 2015Google Scholar
- 12.Harman, American College of Physicians et al. 2014 Arterial imaging outcome and cardiovascular risk factors in recently menopausal women: a randomized trial.Google Scholar
- 13.Uptodate.com, Preparations for menopausal hormone therapy.Google Scholar
- 14.ACOG Committee Opinion 2016, The use of vaginal estrogen in women with a history of estrogen dependent breast cancer.Google Scholar